In conclusion, concurrent positivity for anti-Ro52/TRIM21 and anti-Ro60/SSA antibodies delineates a clinically distinct and immunologically unique RA subgroup characterized by increased disease severity and therapeutic complexity. This evidence concerns the gene TRIM21 and rheumatoid arthritis.